Involvement of sulfatide in beta cells and type 1 and type 2 diabetes

Diabetologia

Volumn 48, Issue 10, 2005, Pages 1957-1962

  Buschard, K ^a   Blomqvist, M ^b   Osterbye, T ^a   Fredman, P ^b  

^a Mental Health Services CPH   (Denmark)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD1; Cytokines; Galactosylceramide; GalCer; Glycosphingolipids; Insulin; Sulfatide; Sulphated lactosylceramide; SulphLacCer; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTIBODY; DIAZOXIDE; FATTY ACID; GLYCOSPHINGOLIPID; IMMUNOSUPPRESSIVE AGENT; INSULIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; SULFATIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; INCIDENCE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LYMPHOCYTE COUNT; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS; SULFOGLYCOSPHINGOLIPIDS;

EID: 26244466348     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1926-9     Document Type: Review

References (54)

1. Fredman P, Vedeler CA, Nyland H, Aarli JA, Svennerholm L (1991) Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J Neurol 238:75-79
2. Buschard K, Josefsen K, Horn T, Fredman P (1993) Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet 342:840
3. Vos JP, Lopes-Cardozo M, Gadella BM (1994) Metabolic and functional aspects of sulfogalactolipids. Biochim Biophys Acta 1211:125-149
4. Fredman P, Mansson JE, Rynmark BM et al (2000) The glycosphingolipid sulfatide in the islets of Langerhans in rat pancreas is processed through recycling: possible involvement in insulin trafficking. Glycobiology 10:39-50
5. Coetzee T, Li X, Fujita N et al (1996) Molecular cloning, chromosomal mapping, and characterization of the mouse UDP-galactose:ceramide galactosyltransferase gene. Genomics 35:215-222
6. Honke K, Tsuda M, Koyota S et al (2001) Molecular cloning and characterization of a human beta-Gal-3′-sulfotransferase that acts on both type 1 and type 2 (Gal beta 1-3/1-4GlcNAc-R) oligosaccharides. J Biol Chem 276:267-274
7. Coetzee T, Fujita N, Dupree J et al (1996) Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 86:209-219
8. Honke K, Hirahara Y, Dupree J et al (2002) Paranodal junction formation and spermatogenesis require sulfoglycolipids. Proc Natl Acad Sci U S A 99:4227-4232
9. Fredman P, Mattsson L, Andersson K et al (1988) Characterization of the binding epitope of a monoclonal antibody to sulphatide. Biochem J 251:17-22
10. Buschard K, Josefsen K, Hansen SV et al (1994) Sulphatide in islets of Langerhans and in organs affected in diabetic late complications: a study in human and animal tissue. Diabetologia 37:1000-1006
11. Buschard K, Josefsen K, Rygaard J, Spitalnik SL (1991) Pancreatic islet-cell epitope recognized by an anti-sulphatide monoclonal antibody. APMIS 99:1151-1156
12. Stein C, Gieselmann V, Kreysing J et al (1989) Cloning and expression of human arylsulfatase A. J Biol Chem 264:1252-1259
13. Osterbye T, Jorgensen KH, Fredman P et al (2001) Sulfatide promotes the folding of proinsulin, preserves insulin crystals, and mediates its monomerization. Glycobiology 11:473-479
14. Blomqvist M, Osterbye T, Mansson JE, Horn T, Buschard K, Fredman P (2003) Selective lack of the C16:0 fatty acid isoform of sulfatide in pancreas of type II diabetic animal models. APMIS 111:867-877
15. Bogdanov M, Dowhan W (1999) Lipid-assisted protein folding. J Biol Chem 274:36827-36830
16. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR (1999) Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339
17. Toyota T, Abe K, Kudo M, Kimura K, Goto Y (1975) Inhibitory effects of synthetic rat C-peptide 1 on insulin secretion in the isolated perfused rat pancreas. Tohoku J Exp Med 117:79-83
18. Buschard K, Hoy M, Bokvist K et al (2002) Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+)-channel activity and Ca(2+)-dependent exocytosis in rat pancreatic beta-cells. Diabetes 51:2514-2521
19. Skak K, Gotfredsen CF, Lundsgaard D, Hansen JB, Sturis J, Markholst H (2004) Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 53:1089-1095
20. Carr RD, Brand CL, Bodvarsdottir TB, Hansen JB, Sturis J (2003) NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes 52:2513-2518
21. Andersson K, Buschard K, Fredman P et al (2002) Patients with insulin-dependent diabetes but not those with non-insulin-dependent diabetes have anti-sulfatide antibodies as determined with a new ELISA assay. Autoimmunity 35:463-468
22. Krischer JP, Cuthbertson DD, Yu L et al (2003) Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 88:103-108
23. Buschard K, Hanspers K, Fredman P, Reich EP (2001) Treatment with sulfatide or its precursor, galactosylceramide, prevents diabetes in NOD mice. Autoimmunity 34:9-17
24. Atkinson MA, Leiter EH (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601-604
25. Buschard K, Diamant M, Bovin LE, Mansson JE, Fredman P, Bendtzen K (1996) Sulphatide and its precursor galactosylceramide influence the production of cytokines in human mononuclear cells. APMIS 104:938-944
26. Bovin LF, Fredman P, Mansson JE, Buschard K, Bendtzen K (1999) In vitro production of cytokines is influenced by sulfatide and its precursor galactosylceramide. FEBS Lett 455:339-343
27. Roeske-Nielsen A, Fredman P, Mansson JE, Bendtzen K, Buschard K (2004) Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol Lett 91:205-211
28. Suzuki Y, Toda Y, Tamatani T et al (1993) Sulfated glycolipids are ligands for a lymphocyte homing receptor, L-selectin (LECAM-1), binding epitope in sulfated sugar chain. Biochem Biophys Res Commun 190:426-434
29. Yang XD, Karin N, Tisch R, Steinman L, McDevitt HO (1993) Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Proc Natl Acad Sci U S A 90:10494-10498
30. Kajihara J, Guoji Y, Kato K, Suzuki Y (1995) Sulfatide, a specific sugar ligand for L-selectin, blocks CCl4-induced liver inflammation in rats. Biosci Biotechnol Biochem 59:155-157
31. Mulligan MS, Miyasaka M, Suzuki Y et al (1995) Anti-inflammatory effects of sulfatides in selectin-dependent acute lung injury. Int Immunol 7:1107-1113
32. Porcelli SA, Modlin RL (1999) The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 17:297-329
33. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA (1997) Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277:339-345
34. Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G (2002) Presentation of the same glycolipid by different CD1 molecules. J Exp Med 195:1013-1021
35. Zajonc DM, Elsliger MA, Teyton L, Wilson IA (2003) Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 Å. Nat Immunol 4:808-815
36. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V (2004) Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 199:947-957
37. Naidenko OV, Maher JK, Ernst WA, Sakai T, Modlin RL, Kronenberg M (1999) Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med 190:1069-1080
38. Burdin N, Brossay L, Koezuka Y et al (1998) Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 161:3271-3281
39. Kent SC, Hafler DA, Strominger JL, Wilson SB (1999) Noncanonical Vα24JαQ T cells with conservative alpha chain CDR3 region amino acid substitutions are restricted by CD1d. Hum Immunol 60:1080-1089
40. Wilson SB, Delovitch TL (2003) Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 3:211-222
41. + T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 92:11931-11934
42. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF (1996) Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 26:2989-2998
43. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100:144-148
44. Wilson SB, Kent SC, Patton KT et al (1998) Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 391:177-181
45. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A (2002) Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110:793-800
46. Hong S, Wilson MT, Serizawa I et al (2001) The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7:1052-1056
47. Sharif S, Arreaza GA, Zucker P et al (2001) Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7:1057-1062
48. Lehuen A, Lantz O, Beaudoin L et al (1998) Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J Exp Med 188:1831-1839
49. Shi FD, Flodstrom M, Balasa B et al (2001) Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A 98:6777-6782
50. Falcone M, Facciotti F, Ghidoli N et al (2004) Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 172:5908-5916
51. Buschard K, Fredman P, Bøg-Hansen E et al (2005) Low serum concentration of sulfatide and presence of sulfated lactosylceramide are associated with type 2 diabetes. Diabet Med 22:1190-1198
52. Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA (2003) Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 27:88-94
53. Blomqvist M, Kaas A, Mansson JE et al (2003) Developmental expression of the type I diabetes related antigen sulfatide and sulfated lactosylceramide in mammalian pancreas. J Cell Biochem 89:301-310
54. Blomqvist M, Carrier M, Andrews T et al (2005) In vivo administration of the C16:0 fatty acid isoform of sulfatide increases pancreatic sulfatide and enhances glucose-stimulated insulin secretion in Zucker fatty (fa/fa) rats. Diabetes Metab Res Rev 21:158-166